Acalabrutinib Metabolite 27
Acalabrutinib Metabolite 27 Basic information
- Product Name:
- Acalabrutinib Metabolite 27
- Synonyms:
-
- Acalabrutinib Metabolite 27
- Acalabrutinib?active?metabolite?M27
- 4-[8-amino-3-[1-oxo-4-[(1-oxo-2-butyn-1-yl)amino]butyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-Benzamide
- ACP-5862
- Acalabrutinib Impurity 1
- Benzamide, 4-[8-amino-3-[1-oxo-4-[(1-oxo-2-butyn-1-yl)amino]butyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-
- Acalabrutinib Metabolite (M27) ACP-5862 D4Q: What is Acalabrutinib Metabolite (M27) ACP-5862 D4 Q: What is the CAS Number of Acalabrutinib Metabolite (M27) ACP-5862 D4
- Acalabrutinib Metabolite 27 (ACP-5862)
- CAS:
- 2230757-47-6
- MF:
- C26H23N7O3
- MW:
- 481.51
- Mol File:
- 2230757-47-6.mol
More
Less
Acalabrutinib Metabolite 27 Chemical Properties
- Density
- 1.34±0.1 g/cm3(Predicted)
- pka
- 11.35±0.70(Predicted)
More
Less
Acalabrutinib Metabolite 27 Usage And Synthesis
Uses
4-[8-Amino-3-[1-oxo-4-[(1-oxo-2-butyn-1-yl)amino]butyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-benzamide is a metabolite of Acalabrutinib (A115605) which is an experimental anti-cancer drug and a selective Bruton''s tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL).
Acalabrutinib Metabolite 27Supplier
ChemStrong Scientific Co.,Ltd
- Tel
- 0755-66853366 13670046396
- sales@chem-strong.com
Nanjing XiZe Biotechnology CO., Ltd.
- Tel
- 025-58362220 15250997978
- 1511893459@qq.com
Artis Biotech Co. Ltd.
- Tel
- 19138486554 18582380095
- sales@artisbio.com
Chengdu Novel Biomedical Co., Ltd.
- Tel
- 028-85255396 18302801538
- cdnovell@163.com
Shanghai Han-Xiang Chemical Co., Ltd.
- Tel
- 15971444841
- amber@biochempartner.com